Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents

Journal of Pharmaceutical Sciences

Volumn 99, Issue 6, 2010, Pages 2664-2671

  Cai, Shuang ^a   Xie, Yumei ^a   Davies, Neal M ^b   Cohen, Mark S ^c   Forrest, M Laird ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Biodegradable polymers; Cancer chemotherapy; Controlled release; Lymphatic transport; Pharmacokinetics; Polymeric drug carrier; Polymeric drug delivery systems

Indexed keywords

CISPLATIN; CREATININE; HYALURONIC ACID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; FEMALE; IC 50; LYMPH NODE; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NONHUMAN; RAT; TISSUE DISTRIBUTION;

EID: 77951551833     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22016     Document Type: Article

References (23)

1. FDA oncology tools approval summary for cisplatin for metastatic ovarian tumors, 2008. Available from: http://www.accessdata.fda.gov/scripts/cder/ onctools/summary.cfm?ID=73 [cited December 12, 2008].
2. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. 2008. Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61:903-909.
3. Stemmler HJ, Kahlert S, Brudler O, Beha M, Muller S, Stauch B, Heinemann V. 2005. High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: A phase II study. Clin Oncol (R Coll Radiol) 17:630-635. (Pubitemid 41700328)
4. Pabla N, Dong Z. 2008. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int 73:994-1007. (Pubitemid 351543900)
5. Safirstein R, Miller P, Guttenplan JB. 1984. Uptake and metabolism of cisplatin by rat kidney. Kidney Int 25:753-758. (Pubitemid 14082180)
6. Shimizu Y, Hasumi K. 1999. Chemotherapy with consecutive low-dose CDDP combined with 5-FU for gynecologic malignancies. Gan To Kagaku Ryoho 26:1564-1574.
7. Zuur CL, Simis YJ, Verkaik RS, Schornagel JH, Balm AJ, Dreschler WA, Rasch CR. 2008. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. Radiother Oncol 89:38-43.
8. Maruo T, Motoyama S, Hamana S, Yoshida S, Ohara N, Yamasaki M, Ku Y. 2008. Percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma. Surg Oncol Clin N Am 17:843-856.
9. Cai S, Xie Y, Bagby TR, Cohen MS, Forrest ML. 2008. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res 147:247-252.
10. Jeong YI, Kim ST, Jin SG, Ryu HH, Jin YH, Jung TY, Kim IY, Jung S. 2008. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci 97:1268-1276.
11. Vantyghem SA, Allan AL, Postenka CO, Al-Katib W, Keeney M, Tuck AB, Chambers AF. 2005. A new model for lymphatic metastasis: Development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes. Clin Exp Metastasis 22:351-361. (Pubitemid 41374291)
12. Maeda M, Takasuka N, Suga T, Uehara N, Hoshi A. 1993. Antitumor activity of a new series of platinum complexes: Trans(+/-)-1,2- cyclohexanediammineplatinum(II) conjugated to acid polysaccharides. Anticancer Drugs 4:167-171. (Pubitemid 23115129)
13. Kobayashi H, Kawamoto S, Choyke PL, Sato N, Knopp MV, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW. 2003. Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. Magn Reson Med 50:758-766. (Pubitemid 37187841)
14. Tejler G, Aspegren K. 1985. Complications and hospital stay after surgery for breast cancer: A prospective study of 385 patients. Br J Surg 72:542-544. (Pubitemid 15065008)
15. Vinton AL, Traverso LW, Jolly PC. 1991. Wound complications after modified radical mastectomy compared with tylectomy with axillary lymph node dissection. Am J Surg 161:584-588.
16. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T. 2005. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 93:678-687. (Pubitemid 41486459)
17. Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP. 2004. A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 10:3386-3395. (Pubitemid 38685444)
18. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 65:271-284. (Pubitemid 30122932)
19. Ogawara K, Un K, Minato K, Tanaka K, Higaki K, Kimura T. 2008. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: Importance of vascular permeability within tumors. Int J Pharm 359:234-240.
20. Fraser JR, Laurent TC. 1989. Turnover and metabolism of hyaluronan. Ciba Found Symp 143:41-53, discussion 53-59, 281-285.
21. Dünne AA, Boerner HG, Kukula H, Schlaad H, Wiegand S, Werner JA, Antonietti M. 2007. Block copolymer carrier systems for translymphatic chemotherapy of lymph node metastases. Anticancer Res 27:3935-3940.
22. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. 2003. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. I. Am Soc Nephrol 14:1-10. (Pubitemid 36026291)
23. Kishimoto S, Kawazoe Y, Ikeno M, Fukushima S, Takeuchi Y. 2005. Continuous exposure to low-dose cisplatin and apoptosis. Biol Pharm Bull 28:1954-1957. (Pubitemid 41437088)